atorvastatin has been researched along with Nephrotic Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kundzina, L; Lejniece, S | 1 |
| Bagga, A; Hari, P; Hari, S; Khandelwal, P; Lakshmy, R; Satpathy, A; Sinha, A; Thergaonkar, R | 1 |
| Beleford, DT; Diab, M; Long, RK; Malloy, MJ; Qubty, WF; Shieh, JT | 1 |
| Corrales, MA; Gonzalez-Santos, P; Moliz, M; Sanchez-Chaparro, MA; Valdivielso, P; Valera, A | 1 |
| Jose, J; Saravu, K; Shastry, BA | 1 |
| Hashimoto, T; Inayama, Y; Iwatsubo, K; Kihara, M; Kokuho, T; Kuji, T; Oshikawa, J; Tamura, K; Tanaka, K; Toya, Y; Umemura, S; Yabana, M; Yanagi, M; Yoshida, S | 1 |
2 trial(s) available for atorvastatin and Nephrotic Syndrome
| Article | Year |
|---|---|
Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
Topics: Adolescent; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Child; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nephrotic Syndrome; Prospective Studies; Serum Albumin, Human; Treatment Outcome | 2018 |
Atorvastatin in dyslipidaemia of the nephrotic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Nephrotic Syndrome; Prospective Studies; Pyrroles | 2003 |
4 other study(ies) available for atorvastatin and Nephrotic Syndrome
| Article | Year |
|---|---|
Klippel-Trenaunay-Weber syndrome with atypical presentation of hypersplenism and nephrotic syndrome: a case report.
Topics: Adult; Allopurinol; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Arteriovenous Fistula; Atorvastatin; Cholecalciferol; Erythrocyte Transfusion; Humans; Hypersplenism; Klippel-Trenaunay-Weber Syndrome; Male; Nephrotic Syndrome; Perindopril; Port-Wine Stain; Vitamins | 2017 |
Schimke immunoosseous dysplasia and management considerations for vascular risks.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Atorvastatin; Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Disease Management; DNA Helicases; Dyslipidemias; Female; Gene Expression; Headache; Humans; Hypertension; Mutation; Nephrotic Syndrome; Osteochondrodysplasias; Primary Immunodeficiency Diseases; Propranolol; Pulmonary Embolism | 2019 |
Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome.
Topics: Adolescent; Atorvastatin; Early Diagnosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Male; Nephrotic Syndrome; Pyrroles; Rhabdomyolysis | 2007 |
Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Behcet Syndrome; Benzimidazoles; Biphenyl Compounds; Dilazep; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nephrotic Syndrome; Pyrroles; Tetrazoles; Vasodilator Agents | 2008 |